Cargando…
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study
SMARCA4-deficient thoracic sarcoma is a newly described entity of thoracic sarcomas with a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology and SMARCA4 gene inactivation. We present a case of a SMARCA4-deficient thoracic sarcoma in a 41-year-old male with a sm...
Autores principales: | Anžič, Nina, Krasniqi, Fatime, Eberhardt, Anna-Lena, Tzankov, Alexandar, Haslbauer, Jasmin Dionne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215992/ https://www.ncbi.nlm.nih.gov/pubmed/34177520 http://dx.doi.org/10.1159/000515416 |
Ejemplares similares
-
Is the case really a SMARCA4‐deficient thoracic sarcoma?
por: Kunimasa, Kei
Publicado: (2020) -
A case of thoracic
SMARCA4‐Deficient undifferentiated tumor successfully treated with combination Ipilimumab–Nivolumab
por: Nakano, Yoshio, et al.
Publicado: (2022) -
Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
por: Takada, Kohichi, et al.
Publicado: (2019) -
Histomorphological patterns of regional lymph nodes in COVID-19 lungs
por: Haslbauer, Jasmin D., et al.
Publicado: (2021) -
Reaktionsmuster der lokoregionären Lymphknoten im Abflussgebiet von COVID-19-Lungen
por: Haslbauer, Jasmin D., et al.
Publicado: (2021)